Patents by Inventor Sreenu Domalapally

Sreenu Domalapally has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
    Patent number: 8080568
    Abstract: This invention relates to 2-pyridyl substituted imidazoles which are inhibitors of the transforming growth factor-? (TGF-?) type I receptor (ALK5) and/or the activin type I receptor (ALK4), methods for their preparation, and their use in medicine, specifically in the treatment and prevention of a disease state mediated by these receptors.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: December 20, 2011
    Assignee: EWHA University - Industry Collaboration Foundation
    Inventors: Dae-Kee Kim, Yhun Yhong Sheen, Chenghua Jin, Chul-Yong Park, Sreenu Domalapally, Sudhakar Rao Kota, Krishnaiah Maddeboina, Subrahmanyam Vura Bala
  • 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
    Patent number: RE47122
    Abstract: This invention relates to 2-pyridyl substituted imidazoles which are inhibitors of the transforming growth factor-? (TGF-?) type I receptor (ALK5) and/or the activin type I receptor (ALK4), methods for their preparation, and their use in medicine, specifically in the treatment and prevention of a disease state mediated by these receptors.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: November 13, 2018
    Assignee: EWHA UNIVERSITY—INDUSTRY COLLABORATION FOUNDATION
    Inventors: Dae-Kee Kim, Yhun Yhong Sheen, Chenghua Jin, Chul-Yong Park, Sreenu Domalapally, Sudhakar Rao Kota, Krishnaiah Maddeboina, Subrahmanyam Vura Bala
  • Methods of treating fibrosis, cancer and vascular injuries
    Patent number: RE47141
    Abstract: This invention relates to use of inhibitors of the transforming growth factor-? (TGF-?) type I receptor (ALK5) and/or the activin type I receptor (ALK4) in treating, preventing, or reducing fibrosis, cancer, and vascular injuries.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: November 27, 2018
    Assignee: EWHA UNIVERSITY—INDUSTRY COLLABORATION FOUNDATION
    Inventors: Dae-Kee Kim, Yhun Yhong Sheen, Chenghua Jin, Chul-Yong Park, Sreenu Domalapally, Sudhakar Rao Kota, Krishnaiah Maddeboina, Subrahmanyam Vura Bala